HC Wainwright Has Negative Estimate for PRAX Q1 Earnings

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) – Investment analysts at HC Wainwright reduced their Q1 2025 EPS estimates for Praxis Precision Medicines in a research report issued to clients and investors on Monday, March 3rd. HC Wainwright analyst D. Tsao now anticipates that the company will earn ($3.18) per share for the quarter, down from their previous estimate of ($2.96). HC Wainwright has a “Buy” rating and a $105.00 price objective on the stock. The consensus estimate for Praxis Precision Medicines’ current full-year earnings is ($10.22) per share. HC Wainwright also issued estimates for Praxis Precision Medicines’ Q2 2025 earnings at ($3.64) EPS, Q3 2025 earnings at ($4.15) EPS, Q4 2025 earnings at ($4.16) EPS, FY2025 earnings at ($15.13) EPS, Q1 2026 earnings at ($4.39) EPS, Q2 2026 earnings at ($4.82) EPS, Q3 2026 earnings at ($4.89) EPS, Q4 2026 earnings at ($4.90) EPS, FY2026 earnings at ($18.99) EPS, FY2027 earnings at ($15.64) EPS, FY2028 earnings at ($15.64) EPS and FY2029 earnings at $23.38 EPS.

Praxis Precision Medicines (NASDAQ:PRAX) last issued its earnings results on Friday, February 28th. The company reported ($2.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.76) by ($0.18). Praxis Precision Medicines had a negative net margin of 9,409.22% and a negative return on equity of 54.86%. The firm had revenue of $7.48 million during the quarter, compared to the consensus estimate of $0.36 million.

A number of other research firms have also recently weighed in on PRAX. Robert W. Baird dropped their price target on Praxis Precision Medicines from $117.00 to $73.00 and set an “outperform” rating on the stock in a research note on Monday. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Praxis Precision Medicines in a research report on Tuesday, February 11th. They issued a “buy” rating and a $111.00 price objective on the stock. Truist Financial reduced their target price on shares of Praxis Precision Medicines from $175.00 to $85.00 and set a “buy” rating for the company in a report on Monday. Wedbush cut shares of Praxis Precision Medicines from a “hold” rating to a “strong sell” rating in a report on Friday, February 28th. Finally, Needham & Company LLC reduced their price objective on Praxis Precision Medicines from $150.00 to $85.00 and set a “buy” rating for the company in a report on Monday. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $123.80.

Praxis Precision Medicines Stock Up 4.5 %

NASDAQ:PRAX opened at $37.85 on Wednesday. Praxis Precision Medicines has a 12-month low of $30.01 and a 12-month high of $91.83. The stock’s 50 day moving average price is $73.74 and its two-hundred day moving average price is $69.30. The firm has a market capitalization of $763.17 million, a price-to-earnings ratio of -3.67 and a beta of 2.76.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. US Bancorp DE grew its position in Praxis Precision Medicines by 35.9% during the third quarter. US Bancorp DE now owns 2,289 shares of the company’s stock worth $132,000 after buying an additional 605 shares in the last quarter. Mesirow Financial Investment Management Inc. bought a new stake in shares of Praxis Precision Medicines during the 3rd quarter valued at $231,000. CIBC Asset Management Inc grew its holdings in shares of Praxis Precision Medicines by 29.2% during the 3rd quarter. CIBC Asset Management Inc now owns 248,939 shares of the company’s stock worth $14,324,000 after purchasing an additional 56,272 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Praxis Precision Medicines in the third quarter worth $217,000. Finally, Charles Schwab Investment Management Inc. raised its stake in Praxis Precision Medicines by 188.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 137,052 shares of the company’s stock valued at $7,886,000 after purchasing an additional 89,578 shares in the last quarter. 67.84% of the stock is owned by institutional investors.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.